CoChat
Sign Up
Cited by 436Cardiovascular Function and Risk FactorsCardiomyopathy and Myosin StudiesGout, Hyperuricemia, Uric Acid

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy

Cappola, Thomas P., Kass, David A., Nelson, Gregory S., Berger, Ronald D., Rosas, Gisele O., Kobeissi, Zoulficar A., Marbán, Eduardo, Hare, Joshua M.·2001·Circulation
DOI 10.1161/hc4501.098928
Open this paper in CoChat — free account

Abstract

Background Dilated cardiomyopathy is characterized by an imbalance between left ventricular performance and myocardial energy consumption. Experimental models suggest that oxidative stress resulting from increased xanthine oxidase (XO) activity contributes to this imbalance. Accordingly, we hypothesized that XO inhibition with intracoronary allopurinol improves left ventricular efficiency in patients with idiopathic dilated cardiomyopathy. Methods and Results Patients (n=9; ejection fraction, 29±3%) were instrumented to assess myocardial oxygen consumption (MV̇ o 2 ), peak rate of rise of left ventricular pressure (dP/dt max ), stroke work (SW), and efficiency (dP/dt max /MV̇ o 2 and SW/MV̇ o 2 ) at baseline and after sequential infusions of intracoronary allopurinol (0.5, 1.0, and 1.5 mg/min, each for 15 minutes). Allopurinol caused a significant decrease in MV̇ o 2 (peak effect, −16±5%; P <0.01; n=9) with no parallel decrease in dP/dt max or SW and no change in ventricular load. The net result was a substantial improvement in myocardial efficiency (peak effects: dP/dt max /MV̇ o 2 , 22±9%, n=9; SW/MV̇ o 2 , 40±17%, n=6; both P <0.05). These effects were apparent despite concomitant treatment with standard heart failure therapy, including ACE inhibitors and β-blockers. XO and its parent enzyme xanthine dehydrogenase were more abundant in failing explanted human myocardium on immunoblot. Conclusions These findings indicate that XO activity may contribute to abnormal energy metabolism in human cardiomyopathy. By reversing the energetic inefficiency of the failing heart, pharmacological XO inhibition represents a potential novel therapeutic strategy for the treatment of human heart failure.

Overview

Integrity signals

Registry

Crossref · 10.1161/hc4501.098928

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 9

  1. 10.1161/circ.93.5.932 · DOI
  2. 10.1161/circ.97.16.1536 · DOI
  3. 10.1161/res.83.4.423 · DOI
  4. 10.1161/res.85.5.437 · DOI
  5. 10.1161/circ.103.5.750 · DOI
  6. 10.1161/circ.92.8.2198 · DOI
  7. 10.1161/circ.94.10.2497 · DOI
  8. 10.1161/circ.97.4.363 · DOI
  9. 10.1161/circ.103.6.826 · DOI

Cited by

Sorted by citations

See all 436

Related

See all

Metadata

Authors
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M.
Affiliations
  • Johns Hopkins University (US)
  • From the Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2001-11-13
Volume
104
Issue
20
Pages
2407-2411
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/hc4501.098928
OpenAlex
W2129194977
Cited by
436
References
31
Citations by year
2026: 3 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 12 · 2021: 14 · 2020: 17 · 2019: 12 · 2018: 12 · 2017: 17 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 27 · 2012: 25
FWCI
11.93
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Johns Hopkins University
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (K08HL003238, K08-HL-03238, R01 HL65455, R01HL065455)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Keywords
allopurinol, idiopathic dilated cardiomyopathy, xanthine oxidase inhibition, myocardial energy metabolism, myocardial oxygen consumption, stroke work, heart failure treatment, xanthine dehydrogenase, oxidative stress
MeSH terms
Allopurinol, Cardiomyopathy, Dilated, Enzyme Inhibitors, Female, Hemodynamics, Humans, Male, Middle Aged, Myocardial Contraction, Myocardium, Oxygen Consumption, Xanthine Oxidase, Oxidative Stress, Ventricular Dysfunction, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review